Point-of-Care Monitoring of Anticoagulation Therapy; Approved Guideline

This document provides guidance to users and manufacturers of point-of-care coagulation devices for monitoring heparin and warfarin anticoagulant therapy, and to ensure reliable results comparable to those obtained by routine clinical laboratory testing.

A guideline for global application developed through the NCCLS consensus process.
NCCLS... Global Consensus Standardization for Health Technologies

NCCLS is an international, interdisciplinary, nonprofit, standards-developing, and educational organization that promotes the development and use of voluntary consensus standards and guidelines within the healthcare community. It is recognized worldwide for the application of its unique consensus process in the development of standards and guidelines for patient testing and related healthcare issues. NCCLS is based on the principle that consensus is an effective and cost-effective way to improve patient testing and healthcare services.

In addition to developing and promoting the use of voluntary consensus standards and guidelines, NCCLS provides an open and unbiased forum to address critical issues affecting the quality of patient testing and healthcare.

PUBLICATIONS

An NCCLS document is published as a standard, guideline, or committee report.

Standard A document developed through the consensus process that clearly identifies specific, essential requirements for materials, methods, or practices for use in an unmodified form. A standard may, in addition, contain discretionary elements, which are clearly identified.

Guideline A document developed through the consensus process describing criteria for a general operating practice, procedure, or material for voluntary use. A guideline may be used as written or modified by the user to fit specific needs.

Report A document that has not been subjected to consensus review and is released by the Board of Directors.

CONSENSUS PROCESS

The NCCLS voluntary consensus process is a protocol establishing formal criteria for:

- the authorization of a project
- the development and open review of documents
- the revision of documents in response to comments by users
- the acceptance of a document as a consensus standard or guideline.

Most NCCLS documents are subject to two levels of consensus—"proposed" and "approved." Depending on the need for field evaluation or data collection, documents may also be made available for review at an intermediate consensus level.

Proposed An NCCLS consensus document undergoes the first stage of review by the healthcare community as a proposed standard or guideline. The document should receive a wide and thorough technical review, including an overall review of its scope, approach, and utility, and a line-by-line review of its technical and editorial content.

Approved An approved standard or guideline has achieved consensus within the healthcare community. It should be reviewed to assess the utility of the final document, to ensure attainment of consensus (i.e., that comments on earlier versions have been satisfactorily addressed), and to identify the need for additional consensus documents.

NCCLS standards and guidelines represent a consensus opinion on good practices and reflect the substantial agreement by materially affected, competent, and interested parties obtained by following NCCLS’s established consensus procedures. Provisions in NCCLS standards and guidelines may be more or less stringent than applicable regulations. Consequently, conformance to this voluntary consensus document does not relieve the user of responsibility for compliance with applicable regulations.

COMMENTS

The comments of users are essential to the consensus process. Anyone may submit a comment, and all comments are addressed, according to the consensus process, by the NCCLS committee that wrote the document. All comments, including those that result in a change to the document when published at the next consensus level and those that do not result in a change, are responded to by the committee in an appendix to the document. Readers are strongly encouraged to comment in any form and at any time on any NCCLS document. Address comments to the NCCLS Executive Offices, 940 West Valley Road, Suite 1400, Wayne, PA 19087, USA.

VOLUNTEER PARTICIPATION

Healthcare professionals in all specialties are urged to volunteer for participation in NCCLS projects. Please contact the NCCLS Executive Offices for additional information on committee participation.
Abstract

Point-of-care coagulation testing (POC-CT), also known as “bedside testing” or “near-patient testing,” is intended to provide test results more rapidly than can be achieved in hospital or reference laboratory settings. This is important in intensive care units, emergency rooms, operating rooms, and outpatient clinics, where it may help to expedite treatment decisions. POCT allows coagulation testing in the home environment, including patient self-testing (PST), thus providing increased access and convenience for the patient and/or caregiver and improving quality of care.

The guideline provides users of POC-CT systems with information and suggestions for good clinical testing practice and for producing reliable test results regardless of where or by whom the test is performed. This document deals with POC-CT performed for monitoring heparin and warfarin therapy.

This publication is protected by copyright. No part of it may be reproduced, stored in a retrieval system, transmitted, or made available in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without prior written permission from NCCLS, except as stated below.

NCCLS hereby grants permission to reproduce limited portions of this publication for use in laboratory procedure manuals at a single site, for interlibrary loan, or for use in educational programs provided that multiple copies of such reproduction shall include the following notice, be distributed without charge, and, in no event, contain more than 20% of the document’s text.

Reproduced with permission, from NCCLS publication H49-A—Point-of-Care Monitoring of Anticoagulation Therapy; Approved Guideline (ISBN 1-56238-540-2). Copies of the current edition may be obtained from NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

Permission to reproduce or otherwise use the text of this document to an extent that exceeds the exemptions granted here or under the Copyright Law must be obtained from NCCLS by written request. To request such permission, address inquiries to the Executive Director, NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

Copyright ©2004. The National Committee for Clinical Laboratory Standards.

Suggested Citation


Proposed Guideline

September 2003

Approved Guideline

July 2004
Committee Membership

Area Committee on Hematology

Bruce H. Davis, M.D.
Chairholder
Maine Medical Center Research Institute
Scarborough, Maine

Samuel J. Machin, MB, Ch.B,
FRCPath, FRCP
Vice-Chairholder
The University College London Hospitals
London, United Kingdom

Dorothy M. Adcock, M.D.
Esoterix Coagulation
Aurora, Colorado

Frank M. LaDuca, Ph.D.
International Technidyne Corporation
Edison, New Jersey

Ginette Y. Michaud, M.D.
Center for Devices and Radiologic Health
Food and Drug Administration
Rockville, Maryland

Albert Rabinovitch, M.D., Ph.D.
Hematology Business Unit
Abbott Diagnostics Division
Santa Clara, California

Maryalice Stetler-Stevenson, M.D., Ph.D.
National Institutes of Health
Bethesda, Maryland

Charles F. Arkin, M.D.
Lahey Clinic
Burlington, Massachusetts

J. David Bessman, M.D.
University of Texas Medical Branch
Galveston, Texas

Sheila Clover, CPT(ASCP)(NCA)
Phlebotomy West
Brentwood, California

Dennis J. Ernst, M.T.(ASCP)
Center for Phlebotomy Education
Ramsey, Indiana

John A. Koepke, M.D.
Durham, North Carolina

Francis Lacombe, M.D., Ph.D.
Hôpital Haut-Lévêque
Pessac, France

Richard A. Marlar, Ph.D.
Oklahoma City VA Medical Center
Oklahoma City, Oklahoma

Diane I. Szamosi, M.A.,
M.T.(ASCP)SH
Greiner Bio-One,
VACUETTE North America, Inc.
Monroe, North Carolina

Lue Van Hove, M.D., Ph.D.
Abbott Laboratories
Abbott Park, Illinois

Subcommittee on Point-of-Care Coagulation Testing

Jack E. Ansell, M.D.
Chairholder
Boston University Medical Center
Boston, Massachusetts

George G. Despotis, M.D.
Washington University School of Medicine
St. Louis, Missouri

Frank M. LaDuca, Ph.D.
International Technidyne Corporation
Edison, New Jersey

Richard A. Marlar, Ph.D.
Denver VA Medical Center
Denver, Colorado

Ginette Y. Michaud, M.D.
FDA Center for Devices/Rad. Health
Rockville, Maryland

David L. Phillips
i-Stat Corp.
East Windsor, New Jersey

Paula J. Santrach, M.D.
Mayo Clinic
Rochester, Minnesota

Advisors

Sue S. Beglinger, M.S., M.T.(ASCP)
University of Wisconsin
Madison, Wisconsin

J. David Bessman, M.D.
University of Texas Medical Branch
Galveston, Texas

Mary F. Cavin
John L. McClellan Memorial VA Hospital
Irvine, California

W. Gregory Cooper
Bio-Rad Laboratories, ECS Division
Indianapolis, Indiana

Catherine Cox, M.D.
Methodist Hospital of Indiana
Indianapolis, Indiana

Amando D’Angelo
H.S. Raffaele
Milan, Italy

Paul A. Foster, M.D.
Abbott Laboratories
Abbott Park, Illinois

Kenneth D. Levy
Roche Diagnostics Corporation
Indianapolis, Indiana

Marilyn Lightfoote
FDA Center for Devices/Rad. Health
Rockville, Maryland

Janice Marks
Health Park Medical Center
Fort Myers, Florida

Valerie L. Ng, Ph.D., M.D.
San Francisco General Hospital
San Francisco, California

John D. Olson, M.D.
University of Iowa Hospitals and Clinics
Iowa City, Iowa

M.T.(ASCP)SH
Greiner Bio-One,
VACUETTE North America, Inc.
Monroe, North Carolina

Lue Van Hove, M.D., Ph.D.
Abbott Laboratories
Abbott Park, Illinois

Staff

David E. Sterry, M.T.(ASCP)
NCCLS
Wayne, Pennsylvania

Donna M. Wilhelm
NCCLS
Wayne, Pennsylvania

Melissa A. Lewis
NCCLS
Wayne, Pennsylvania
Acknowledgement

NCCLS gratefully acknowledges the late Dr. J. Heinrich Joist, St. Louis University Health Sciences Center, who served as the Chairholder from the development through the completion of the proposed-level guideline.
# Contents

Abstract ....................................................................................................................... i  
Committee Membership .............................................................................................. iii  
Foreword ....................................................................................................................... vii  

1 Scope .......................................................................................................................... 1  

2 Introduction ................................................................................................................... 1  

3 Standard Precautions ................................................................................................... 1  

4 Definitions .................................................................................................................... 1  

5 Point-of-Care Coagulation Testing (POC-CT)—General Considerations ...................... 6  

6 Quality Management: General Considerations for Point-of-Care Coagulation Testing ........ 6  

   6.1 Operators, Materials, and Performance of POC-CT .................................................. 6  

   6.2 Training ................................................................................................................... 7  

   6.3 Quality Control and Proficiency Testing ................................................................... 8  

   6.4 Result Recording and Reporting ............................................................................. 9  

7 Monitoring Heparin Therapy .......................................................................................... 10  

   7.1 Introduction .......................................................................................................... 10  

   7.2 Blood Specimen Collection and Handling ............................................................. 11  

   7.3 POC-CT Systems Used for Monitoring Heparin Therapy ........................................ 11  

   7.4 Specific Applications ............................................................................................ 14  

8 Monitoring Warfarin Therapy ..................................................................................... 15  

   8.1 Introduction .......................................................................................................... 15  

   8.2 Blood Specimen Collection and Handling ............................................................. 15  

   8.3 Test Systems Used for Monitoring Warfarin Therapy .............................................. 16  

   8.4 Specific Applications ............................................................................................ 18  

   8.5 Result Recording and Reporting ............................................................................. 19  

References ..................................................................................................................... 20  

Summary of Delegate Comments and Subcommittee Responses ..................................... 22  

The Quality System Approach ....................................................................................... 26  

Related NCCLS Publications ......................................................................................... 27
Foreword

Medical conditions, physical location of the patient, and treatment regimens often require test results to be obtained quickly, so appropriate medical care can be administered expeditiously. Laboratory medicine professionals are challenged by the increasing demands for providing faster turnaround of test results, without compromising accuracy. The need to provide test results at greater convenience to, and increased efficiency for, the patient/caregiver without compromising cost-effectiveness is also recognized.

With the introduction of portable devices capable of producing results within seconds or minutes, point-of-care testing (POC—also referred to as “near-patient testing” or “bedside testing”), has been evolving as one way to meet these demands. Because of the potentially serious consequences of inaccurate test results, it is essential that results are accurate and reliable.

One of the challenges facing the healthcare community is acceptance of the idea that clinical coagulation testing, traditionally performed by and under the supervision of trained laboratory professionals, may be performed by personnel not trained in clinical laboratory practice or by patients/caregivers in the home. However, it is the responsibility of the manufacturer to provide test systems capable of delivering accurate results when used properly. Professionals in laboratory medicine should support high-quality point-of-care coagulation testing (POC-CT) services. POC-CT has been, and will continue to be implemented in different sites within the hospital, e.g., operating room, emergency room, intensive care unit, postsurgical recovery room, hemodialysis unit, ambulatory care site, and the patient’s home. The selection of patients for patient self-testing (PST) is the responsibility of the treating physician.

This document provides information to users on how to proceed in the evaluation, implementation, and monitoring of POC-CT, and deals only with the use of POC-CT in monitoring of anticoagulant therapy. It does not address issues related to the use of POC-CT in the evaluation of patients with suspected bleeding disorders. The guideline was written under the assumption that most users may not be laboratory professionals and provides important definitions, procedures, and recommendations. The format is designed to be easy to follow for the lay user.

This document relates closely to NCCLS documents EP18—*Quality Management for Unit-Use Testing* and AST2—*Point-of-Care In Vitro Diagnostic (IVD) Testing*. Please refer to these documents for additional information.

*Note on Terminology*

NCCLS, as a global leader in standardization and harmonization, is firmly committed to achieving global harmonization wherever possible. Harmonization is a process of recognizing, understanding, and explaining differences while taking steps to achieve worldwide uniformity. NCCLS recognizes that medical conventions in the global metrological community have evolved differently in the United States, Europe, and elsewhere; that these differences are reflected in NCCLS, ISO, and CEN documents; and that legally required use of terms, regional usage, and different consensus timelines are all obstacles to harmonization. In light of this, NCCLS recognizes that harmonization of terms facilitates the global application of standards and is an area of immediate attention. Implementation of this policy must be an evolutionary and educational process that begins with new projects and revisions of existing documents.

In order to align the terminology used in H49-A with ISO, the term “trueness” is used in this document when referring to the closeness of the agreement between the average value from a large series of measurements to a true value of a measurand. The term “accuracy,” in its metrological sense, refers to the closeness of the agreement between the result of a (single) measurement and a true value of a measurand, thus comprising both random and systematic effects.
All terms and definitions will be reviewed again for consistency with international use, and revised appropriately during the next scheduled revision of this document.

The Subcommittee on Point-of-Care Coagulation Testing appreciates the opinions of manufacturers and users of POC-CT devices. We encourage all to participate in the consensus process by submitting written comments on content and format to the NCCLS Executive Offices. The subcommittee will consider all comments when it revises this guideline for the next edition.

**Key Words**

Calibration, point-of-care testing, quality assurance, quality control, safety
Point-of-Care Monitoring of Anticoagulation Therapy; Approved Guideline

1 Scope

This document deals only with the use of POC-CT in monitoring of anticoagulant therapy with unfractionated heparin (hereafter called “heparin”) and warfarin. It does not address issues related to the use of POC-CT in the evaluation of patients with suspected hemostatic disorders or use of other anticoagulants. There are many potential sites for POC-CT, such as hospitals, physicians’ offices, and patients’ homes. Those performing POC-CT may include healthcare professionals and patient caregivers, as well as patients.

2 Introduction

Advances in technology and the development of microtechniques and portable test instruments have made it possible to move medical testing closer to the patient. Point-of-care coagulation testing (POC-CT), is intended to provide test results more rapidly, efficiently, and conveniently than can be achieved in the clinical laboratory. This is particularly important in intensive care units, emergency rooms, operating rooms, and outpatient clinics where it may help expedite treatment decisions. POC-CT may also provide greater access to testing for the patient and/or caregiver, whether in the clinic or home setting. POC-CT may also reduce errors due to incorrect or delayed test result transmission to the patient/caregiver and thus improve overall quality of care. The guideline provides information and suggestions for good medical testing practice to produce accurate test results regardless of where, and by whom, testing is performed.

3 Standard Precautions

Because it is often impossible to know what might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all infectious agents and thus are more comprehensive than universal precautions which are intended to apply only to transmission of blood-borne pathogens. Standard and universal precaution guidelines are available from the U.S. Centers for Disease Control and Prevention (Guideline for Isolation Precautions in Hospitals. Infection Control and Hospital Epidemiology. CDC. 1996;17(1):53-80 and MMWR 1988;37:377-388). For specific precautions for preventing the laboratory transmission of all infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all infectious disease, refer to the most current edition of NCCLS document M29—Protection of Laboratory Workers from Occupationally Acquired Infections.

4 Definitions

Accuracy (of measurement) – Closeness of the agreement between the result of a measurement and a true value of the measurand (VIM93); NOTE: See Measurand.

Activated clotting time, ACT – A global coagulation test which is particularly sensitive to abnormalities in the intrinsic blood coagulation pathway and the anticoagulant activity of heparin; NOTE: The ACT is a measurement of the time in seconds required for a clot to form in a native (i.e., nonanticoagulated) blood specimen which has been exposed to a contact activator of the intrinsic phase blood coagulation pathway.